These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3260357)

  • 1. Treating multiple sclerosis with monoclonal antibodies: the cons.
    Champlin RE
    Neurology; 1988 Jul; 38(7 Suppl 2):47-9. PubMed ID: 3260357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression with monoclonal antibodies in multiple sclerosis.
    Hafler DA; Weiner HL
    Neurology; 1988 Jul; 38(7 Suppl 2):42-7. PubMed ID: 3260356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating multiple sclerosis with monoclonal antibodies.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2008 Mar; 8(3):433-55. PubMed ID: 18345973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
    Dawson DM; Carter JL; Hafler DA; Weiner HL
    Riv Neurol; 1987; 57(2):88-91. PubMed ID: 3039645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis.
    Hafler DA; Weiner HL
    Ann Neurol; 1987 Jul; 22(1):89-93. PubMed ID: 3498435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug insight: using monoclonal antibodies to treat multiple sclerosis.
    Hohlfeld R; Wekerle H
    Nat Clin Pract Neurol; 2005 Nov; 1(1):34-44. PubMed ID: 16932490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
    Buttmann M
    Expert Rev Neurother; 2010 May; 10(5):791-809. PubMed ID: 20420497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Open therapeutic trial of anti-T CD4 monoclonal antibody in multiple sclerosis].
    Rumbach L; Racadot E; Bataillard M; Galmiche J; Henlin JL; Trutmann M; Ziegler F; Wijdenes J
    Rev Neurol (Paris); 1994; 150(6-7):418-24. PubMed ID: 7747009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New immunosuppressants with potential implication in multiple sclerosis.
    Gonsette RE
    J Neurol Sci; 2004 Aug; 223(1):87-93. PubMed ID: 15261567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis and Natalizumab.
    Fiore D
    Am J Ther; 2007; 14(6):555-60. PubMed ID: 18090880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current evidence and therapeutic strategies for multiple sclerosis.
    Wingerchuk DM
    Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients.
    Racadot E; Rumbach L; Bataillard M; Galmiche J; Henlin JL; Truttmann M; Herve P; Wijdenes J
    J Autoimmun; 1993 Dec; 6(6):771-86. PubMed ID: 8155256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11).
    Henrickson M; Reid J; Bellet JS; Sawchuk SS; Hirsch R
    Transplantation; 1995 Oct; 60(8):828-35. PubMed ID: 7482743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocytotoxic antibody in multiple sclerosis: activity against T cell subsets and correlation with disease activity.
    Scott CF; Spitler LE
    Clin Exp Immunol; 1983 Jul; 53(1):133-9. PubMed ID: 6223730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azathioprine in multiple sclerosis: the cons.
    Silberberg DH
    Neurology; 1988 Jul; 38(7 Suppl 2):24-7. PubMed ID: 3290710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current therapy of multiple sclerosis. Therapy with monoclonal antibodies to T-cell antigens (CD3, CD4, CD52)].
    Schmidt S; Hohlfeld R
    Nervenarzt; 1996 Feb; 67(2):170-6. PubMed ID: 8851300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of anti-B7-1 and anti-B7-2 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease.
    Inoue A; Koh CS; Yamazaki M; Yagita H
    J Immunol; 1999 Dec; 163(11):6180-6. PubMed ID: 10570309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.
    Rep MH; van Oosten BW; Roos MT; Adèr HJ; Polman CH; van Lier RA
    J Clin Invest; 1997 May; 99(9):2225-31. PubMed ID: 9151795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the rationale for immunomodulating therapies in multiple sclerosis.
    Lisak RP
    Neurology; 1988 Jul; 38(7 Suppl 2):5-8. PubMed ID: 3290714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.